October 2, 2012 — New gout guidelines from the American College of Rheumatology are meant to improve gout management by providing clinicians with clear, readily implemented guidance on urate-lowering ...

New research indicates that a drug commonly prescribed for gout may also lower the risk of heart attack and stroke when taken at an appropriate dose.Researchers from the UK, Sweden and Italy analysed ...

Please provide your email address to receive an email when new articles are posted on . Traditionally within the purview of rheumatology, gout can appropriately be managed by nephrologists for ...

Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...

Some advice was okay to an extent. Others were clearly a money grab.

Atom’s lingdolinurad (ABP-671), a URAT1 inhibitor, is in late stage global clinical trials for chronic gout and ABP-745, an anti-inflammatory drug, is in multi-country Phase 2 trials for acute gout ...